Press Enter to Main Content
您的瀏覽器似乎不支援JavaScript語法,但沒關係,這裡的JavaScript語法並不會影響到內容的陳述, 如需要選擇字級大小,IE6請利用鍵盤按住ALT鍵+ V → X → (G)最大(L)較大(M)中(S)較小(A)小,來選擇適合您的文字大小, 而IE7或Firefox瀏覽器則可利用鍵盤 Ctrl + (+)放大(-)縮小來改變字型大小,如需要回到上一頁可使用瀏覽器提供的 Alt+左方向鍵(←) 快速鍵功能,列印可使用瀏覽器提供的(Ctrl+P)功能。
  • facebook
  • line
  • twitter
  • Print
  • Back

International Series of Biomedical Forums: Regulatory Science BIO Week starts this November

  • Data Source:Ministry of Health and Welfare
  • Created:2015-11-03
  • Last Updated:2017-01-11

In response to the Executive Yuan's "Biological Economic Industrial Development Project" launched this year (2015), the Food and Drugs Administration (FDA) will hold the “Regulatory Science BIO Week” from November 16-20. This series of international forums will lead to further development of Taiwan's medical biotech, creating international standards for a good regulatory environment. These forums will cultivate Taiwan's emerging technologies, promote innovative worldwide product distribution, and accelerate growth of the biotech industry. 

The first forum will take place on November 16-17, entitled "Scientific Forum on the Prospects for Biopharmaceuticals International Regulation." This fourm will be held at the conference hall of the GIS MOTC Convention Center to welcome the beginning of the Regulatory Science BIO Week. The topics covered here include global biopharmaceuticals as well as the latest developments and regulatory reviews of vaccines. Speakers include representatives from the United States, the European Union, Japan, Korea, international pharmaceutical companies, and new, domestic biological drug companies. There, participants will be introduced to regulatory science assessments, and recent innovations and breakthroughs in biopharmaceuticals and vaccine R&D will be shared. 

This is then followed by the "Regenerative Medicine Technology, Ethics, and Law Seminar" at the lecture hall of the Taiwan Research-based Biopharmaceutical Manufacturers Association (TRPMA) on the 18th, where it is expected to gather members of the Human-Trials Institutional Review Board (HTIRB) to address the growing number of studies on cell therapy, gene therapy, tissue engineering and other high-tech product development in order to reach a consensus on the importance of ethical review and the fundamentals of their scientific development. This will aid in the development of domestic regenerative medicine. 

The “Regulatory Science BIO Week” will finish with the "Cell Therapy International Regulatory Science Forum" held on the 19th and 20th at the Chang Yung-Fa Foundation International Conference Centre. Due to the vigorous development of cell therapy research and development in Taiwan, the FDA invited regulatory officials from the USA, EU, Japan, Korea, Singapore, and China to Taiwan to achieve cooperation on international regulations on the science involved and to allow domestically developed cellular therapy products to be approved to go on the market as soon as possible. There, the officials will be introduced to cell therapy management techniques. In addition, well-known cell therapy companies from the USA, Japan, and South Korea will share their product approval and listing experiences. At the same time, this forum will increase attention for cancer immunotherapy through inviting international experts and anti-cancer drug development companies to share their research and experiences in clinical use. This forum is expected to bring a new and proper understanding of immunotherapy to Taiwan. 

In response to the global trend of using bioeconomy to address aging populations and improve public health, national health authorities have developed forward-looking assessment regulations for biological products and regenerative medicine in order to meet the urgent need for more medical care. For the Regulatory Science BIO Week agenda and registration information, please search the FDA related seminar website: http://www.fda.gov.tw/TC/siteList.aspx?sid=4577 The forum series is expected to be brilliant, and all are welcome.